A Dangerous Consequence of the 21st Century Cures Act

We are huge proponents of the 21st Century Cures Act, as it does so much for the rare community. However, there has been an unintended consequence of it’s 2016 passing for the PI community on Medicare.

In short, PI patients on Medicare and receiving subcutaneous immunoglobulin therapy (SCIG) may no longer have access to their immunoglobulin due to stipulations in 21st Century Cures. Effective January 2017, the bill reduces reimbursement for medical equipment like those used in immunoglobulin infusions. The Immune Deficiency Foundation foresaw this issue and fought hard for the PI community to ensure reimbursement for other services was added into the legislation. While they did achieve these goals, Congress suddenly delayed these provisions by four years.

Because of this, the life-saving treatment and therapy is no longer available by some specialty pharmacies to Medicare beneficiaries.

Do you want to help? Let your Congressperson know that they need to accelerate these Medicare benefits by 2018, as opposed to 2021. You can also sign up for IDF Action Alerts which will notify you when to contact your Congresspersons about this.

Jessica Gladwell

Jessica Gladwell

Jessica Gladwell is one of PW's consultants and patient editors. She has lived with late-stage, chronic Lyme and POTS since circa 2002. She has also served as a caregiver to close family members with late-stage, chronic Lyme. Before diagnosis, she served as a business consultant for a large corporation and PM for a small digital branding agency. Now, she is proactive in the rare and neurological disease community, spreading awareness and advising on matters of health and lifestyle when living with a chronic illness.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email
Close Menu